![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the g... Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. Show more
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (βAvenueβ or the βCompanyβ), a specialty pharmaceutical company focused on the development and commercialization...
WORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (βMustangβ or the βCompanyβ) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating todayβs...
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (βAvenueβ or the βCompanyβ), a specialty pharmaceutical company focused on the development and commercialization...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (βFortressβ), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...
Fortressβ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025...
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (βJourney Medicalβ or βthe Companyβ) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
βΒ Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 β MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI...
Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV Clinical...
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a...
Period β | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.29 | -14.6464646465 | 1.98 | 2.05 | 1.66 | 303325 | 1.87802751 | CS |
4 | -0.2 | -10.582010582 | 1.89 | 2.05 | 1.66 | 183470 | 1.87834147 | CS |
12 | -0.47 | -21.7592592593 | 2.16 | 2.17 | 1.6306 | 191449 | 1.84715897 | CS |
26 | -0.79 | -31.8548387097 | 2.48 | 4.43 | 1.63 | 356134 | 2.18668414 | CS |
52 | -8.81 | -83.9047619048 | 10.5 | 10.65 | 1.24 | 478360 | 4.05342229 | CS |
156 | -51.41 | -96.8173258004 | 53.1 | 57.15 | 1.24 | 500486 | 17.19322205 | CS |
260 | -25.46 | -93.7753222836 | 27.15 | 91.5 | 1.24 | 646943 | 35.49011513 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions